1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

BioNotebook: Dyax, MacroGenics, Vivaldi and Rexahn

 
• By Mandy Jackson

Dyax prices $60m offering; MacroGenics surges in first day of trading; Vivaldi acquires vaccine assets; and Rexahn licenses academic drug delivery platform.

Dyax prices $60m offering; MacroGenics surges in first day of trading; Vivaldi acquires vaccine assets; and Rexahn licenses academic drug delivery platform.

Dyax stock sees small dip then gains as company prices $60m offering

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.

Enanta Plans Phase III Trial Of Zelicapavir Despite Primary Endpoint Miss

 
• By Alaric DeArment

The company announced Phase IIb results for the RSV drug that showed positive data across multiple key secondary endpoints, some of which could serve as a primary endpoint in Phase III.

Having Steadied GSK’s Ship, Walmsley To Step Down As Chief

 
• By Kevin Grogan

Chief commercial officer Luke Miels to take over in 'seamless succession'.

Seres Cuts Jobs To Fund Next Microbiome Bet As Cash Runs Low

 
• By Manas Mishra

The biotech is to cut a quarter of its workforce, extending its cash runway to Q2 2026 as it plans a Phase II study for its live biotherapeutic to prevent bloodstream infections.

More from Therapy Areas

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

Boehringer’s Jascayd Approval Brings New Mechanism To IPF

 
• By Jessica Merrill

The PDE4B inhibitor brings a new mechanism of action to the challenging respiratory disease and is the first drug approved for the indication in more than a decade.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.